Antibiotic exposure at the infection site in periprosthetic joint infections

Recruiting

• Conditions: 10004018; infection at the site of the prosthesis; Periprosthetic joint infections

• Registration Number: NL-OMON54617
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 120

Inclusion Criteria

- Age >= 18 years.
- Written informed consent has been obtained from the patient or their legally
authorized representative.
- Suffering from periprosthetic (hip or knee) joint infections and therefore
treated with one of the following antibiotics as part of the one-stage wo-stage
arthroplasty exchange:
IV: vancomycin, flucloxacillin or cefuroxime
Oral: flucloxacillin, clindamycin or co-trimoxazole or ciprofloxacine
- Patients undergoing a two-stage implant exchange of hip or knee with or
without antibiotic free interval prior to re-implantation.
- Able and willing to undergo joint punctures and venous blood sampling during
and, in case of an antibiotic free interval, at the end of the six-weeks
antibiotic treatment.

Exclusion Criteria

- Unable to draw samples for study purposes; Except when a patient received a
vancomycin-loaded spacer, then they will remain included.
- Language barriers.
- The use of the target antibiotics at the start of study participation (and
therefore at the start of the antibiotic treatment as part of the two-stage
arthroplasty exchange).
- The use of drugs interacting with the target antibiotics.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified